Merck's mevinolin
Executive Summary
Mevacor is trademark selected for Merck's cholesterol lowering agent mevinolin. Mevinolin, now in clinicals, was described by Merck in its 1985 annual report as the "lead compound" in its artherosclerosis drug pipeline. At a 1984 NIH Consensus conference, mevinolin was characterized as potentially useful in controlling severe and refractory forms of hypercholesterolemia.